covaxin | Zee News

Advertisement

Covaxin News

17 May 2024

Over 30% Covaxin Takers Report Adverse Effect, Says BHU Study - Check Details

The most prevalent AESIs in adolescents included new-onset skin and subcutaneous disorders (10.5 per cent) Serious AESI, which included stroke and Guillain-Barre syndrome, was reported in one per cent of individuals Recently, AstraZeneca admitted in the UK High Court about a rare risk of blood clot disorder due to its Covid vaccine

10 Aug 2022

Corbevax cleared as Covid booster dose for Covaxin, Covishield recipients

Govt clears Corbevax as Covid-19 booster dose for adults vaccinated with Covaxin, Covishield Health Ministry's approval is based on the recommendations made by the NTG Corbevax is currently being used to inoculate children in the age group of 12 to 14 years under the COVID-19 immunisation programme.

04 Jun 2022

CORBEVAX becomes first vaccine in India to get approval for COVID booster dose

CORBEVAX has become the first vaccine in India to get DCGI approval for COVID-19 booster dose. People who are 18 years & above & have already taken two doses of either COVISHIELD or COVAXIN can now receive a dose of CORBEVAX. The vaccine can be taken after 6 months of two doses of Covaxin or Covishield vaccines for restricted use in emergency situation.

26 May 2022

Germany clears Covaxin, no vaccination proof needed from June 1 for fliers

Germany has cleared the Bharat Biotech’s Covaxin Now, fliers won’t need to show vaccination proof now from June 1 This was also confirmed by German Ambassador Walter J Lindner

07 May 2022

Sputnik booster dose approved in India, over 6.5 lakh people eligible: Report

Sputnik booster dose has been approved in India. Over 6.5 lakh people who have received Sputnik vaccine will be eligible to take the booster dose. India had earlier approved a third dose of COVID vaccines – Covaxin and Covishield – for adults.

05 May 2022

Bharat Biotech seeks approval for Covaxin booster trials for 2-18 age group

Bharat Biotech has sought nod for conducting booster dose trials of Covaxin for 2-18 age group. So far 2,88,62,660 precaution doses to the eligible beneficiaries.

26 Apr 2022

Vaccine Breaking : DCGI grants emergency approval to Covaxin and Corbevax for children below 12

In India, now even 5-year-old children can be given vaccinated against coronavirus. Corbevax vaccine of Biological E Company has been approved for those between 5 to 12 years of age while Covaxin will be given to children between 6 to 12 years of age. These vaccines are administered in two doses each of which is given at an interval of 28 to 40 days

Fourth wave scare

26 Apr 2022

DCGI gives emergency use nod to Covaxin for kids aged 6-12

The Drugs Controller General of India (DCGI) has given a restricted emergency use authorisation to Bharat Biotech's Covaxin for children aged 6-12 years, ANI news agency reported on Tuesday (April 26, 2022).

08 Apr 2022

Japan recognizes India's Covaxin to facilitate travel between both countries

Covaxin is developed indigenously by the Bharat Biotech India and Japan acknowledged the progress in the ongoing projects in Bangladesh

08 Apr 2022

WHO’s supply suspension of Covaxin to impact travel by people? Details here

Covaxin, an indigenous Covid-19 vaccine, is produced by Hyderabad-based Bharat Biotech. "I don`t think that`s a cause for worry at all," MEA spokesperson Arindam Bagchi said.

04 Apr 2022

WHO's suspension of Covaxin supply meant only for UN agencies: Sources

The Hyderabad based Bharat Biotech`s anti-Covid Vaccine, Covaxin has been suspended by WHO under the Covax facility, announced the UN health body on Saturday, attributing it to deficiencies in manufacturing practices.

04 Apr 2022

No impact on efficacy and safety of Covaxin, clarifies Bharat Biotech

Bharat Biotech said there were no issues with its Covid-19 vaccine or its certification. The data available to WHO, indicate the vaccine is effective and no safety concern exists, informed Bharat Biotech.

03 Apr 2022

WHO suspends UN supply of Bharat Biotech's Covaxin vaccine for Covid-19

The WHO said the Bharat Biotech vaccine is effective and no safety concerns exist, but the suspension of production for export will result in the interruption of Covaxin supply.

19 Feb 2022

Covaxin to be evaluated as Covid-19 vaccine candidate in US: Bharat Biotech

Ocugen, Inc is co-developing Bharat Biotech`s Covaxin vaccine candidate for COVID-19 in USA and Canada

COVID-19 vaccine

27 Jan 2022

DCGI grants regular market approval to Covishield, Covaxin, details here

DCGI has granted approval under New Drugs and Clinical Trials Rules, 2019. Private hospitals and clinics will be able to purchase these Covid-19 vaccines.

26 Jan 2022

Covishield, Covaxin likely to be capped at Rs 275 after regular market nod

Covaxin and Covishield were granted Emergency Use Authorisation (EUA) on January 3 last year Serum Institue of India had submitted application to DCGI seeking regular market approval for Covishiled

20 Jan 2022

Govt panel recommends regular market approval for Covishield, Covaxin

An expert panel of India's central drug authority on Wednesday recommended granting regular market approval to Covid vaccines Covishield and Covaxin, which are currently only authorised for emergency use in the country, subject to certain conditions, official sources said.

COVID-19 vaccine

14 Jan 2022

No Covid vaccine shortage in Maharashtra, Centre refutes media reports

The Centre said media reports are "not factually correct and do not reflect the correct picture of the available stock of balance and unutilised Covid vaccine doses with Maharashtra".

12 Jan 2022

Covaxin booster shot neutralises Omicron, says Bharat Biotech

The study was conducted at the Emory Vaccine Center in Atlanta based on blood serum collected from 13 individuals, 28 days after their booster shot, the Bharat Biotech said.

08 Jan 2022

Covaxin booster dose trial shows 'long-term safety': Bharat Biotech

Based on emerging data, Bharat Biotech believes that a third dose may be beneficial to maintain the highest levels of protection.

Loading...

NEWS ON ONE CLICK